Add Yahoo as a preferred source to see more of our stories on Google. Science just scored a win regarding the fight against end-stage kidney disease. The eGenesis company of Cambridge announced Sept.

IND supports Phase 1/2/3 study that will evaluate safety and efficacy at 24 weeks The first patient in the ongoing Multi-Patient Expanded Access study has surpassed seven months kidney function; a ...

Dr. Barth brings over 25 years of industry experience within the biotech and pharmaceutical sectors leading clinical development of transformational therapies eGenesis, a biotechnology company ...

- Transplant was conducted at Massachusetts General Hospital and authorized by the U.S. FDA under a single Expanded Access protocol CAMBRIDGE, Mass.--(BUSINESS WIRE)--eGenesis, a biotechnology company ...

In a landmark move, the US Food and Drug Administration (FDA) has given biotech company eGenesis the go-ahead to conduct a broader human trial in pig-to-human kidney transplants, marking a significant ...

Biotech company eGenesis recently announced its implanted a pig kidney into a second human patient. This animal-to-human organ transplant, or xenotransplant, was made possible through advancements in ...

A Cambridge biotech company and Boston doctors have received federal approval to start the nation’s first clinical trial of genetically engineered pig kidney transplants in people with end-stage ...

MASS GENERAL RIGHT NOW. DANNY AND DOCTORS HERE AT MASS GENERAL HAVE SUCCESSFULLY PERFORMED THREE TRANSPLANTS OF PIG KIDNEYS INTO HUMANS, AND A NEW FDA APPROVAL MAKES IT POSSIBLE FOR MORE PATIENTS TO ...

A biotech company recently announced that it's implanted another pig kidney into a human recipient. Here's what to know. Jesse Orrall (he/him/his) is a Senior Video Producer for CNET. He covers future ...